EPS for NeoGenomics, Inc. (NEO) Expected At $0.02; Norwood Financial Has 10.25 Sentiment

February 18, 2018 - By Vivian Currie

Analysts expect NeoGenomics, Inc. (NASDAQ:NEO) to report $0.02 EPS on February, 28.They anticipate $0.01 EPS change or 33.33% from last quarter’s $0.03 EPS. NEO’s profit would be $1.61M giving it 94.00 P/E if the $0.02 EPS is correct. After having $-0.02 EPS previously, NeoGenomics, Inc.’s analysts see -200.00% EPS growth. The stock decreased 1.05% or $0.08 during the last trading session, reaching $7.52. About 234,103 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since February 18, 2017 and is downtrending. It has underperformed by 30.16% the S&P500.

Norwood Financial Corp. operates as the bank holding firm for Wayne Bank that provides various banking services and products. The company has market cap of $192.29 million. It accepts a range of deposit products, such as interest-bearing and noninterest-bearing transaction accounts, statement savings and money market accounts, and certificate of deposits. It has a 23.65 P/E ratio. The firm also offers various loans, which include commercial loans comprising lines of credit, revolving credit, term loans, mortgages, secured lending products, and letter of credit facilities; construction loans for commercial construction projects and single-family residences; land loans; consumer loans; mortgage lending to finance principal residences and second home dwellings; and indirect dealer financing of new and used automobiles, boats, and recreational vehicles.

Among 11 analysts covering NeoGenomics (NASDAQ:NEO), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. NeoGenomics had 17 analyst reports since September 3, 2015 according to SRatingsIntel. On Friday, May 26 the stock rating was maintained by Roth Capital with “Buy”. The firm has “Buy” rating by BTIG Research given on Friday, May 26. Roth Capital reinitiated NeoGenomics, Inc. (NASDAQ:NEO) on Wednesday, May 11 with “Buy” rating. The firm earned “Neutral” rating on Monday, September 11 by BTIG Research. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Buy” rating by Roth Capital on Thursday, September 3. Cantor Fitzgerald initiated the stock with “Overweight” rating in Thursday, December 15 report. On Wednesday, July 27 the stock rating was downgraded by BTIG Research to “Neutral”. The firm has “Buy” rating by TH Capital given on Monday, October 26. The rating was initiated by First Analysis with “Overweight” on Tuesday, October 4. William Blair maintained the stock with “Outperform” rating in Sunday, September 6 report.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $604.68 million. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It currently has negative earnings. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

Investors sentiment increased to 1.28 in Q3 2017. Its up 0.10, from 1.18 in 2017Q2. It improved, as 11 investors sold NeoGenomics, Inc. shares while 36 reduced holdings. 21 funds opened positions while 39 raised stakes. 62.50 million shares or 3.94% more from 60.13 million shares in 2017Q2 were reported. Dimensional Fund Ltd Partnership reported 602,806 shares. 429,372 are held by Columbus Circle Investors. Strs Ohio invested in 0.01% or 300,000 shares. Wells Fargo Co Mn holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 89,392 shares. Tower Rech Capital Lc (Trc) stated it has 0% in NeoGenomics, Inc. (NASDAQ:NEO). Falcon Point Lc holds 2.03% or 1.61M shares. Price T Rowe Associates Inc Md owns 14,746 shares for 0% of their portfolio. Millrace Asset Grp Inc reported 116,422 shares. Finemark National Bank & Trust & stated it has 0.3% in NeoGenomics, Inc. (NASDAQ:NEO). Emerald Mutual Fund Advisers Trust stated it has 0.52% in NeoGenomics, Inc. (NASDAQ:NEO). Us Bancshares De has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 2,865 shares. 11,385 were accumulated by Jefferies Group Ltd Limited Liability Company. 3.90M were accumulated by Blackrock Inc. Voya Investment Mgmt Limited Com stated it has 0% in NeoGenomics, Inc. (NASDAQ:NEO). Legacy Capital Prtnrs holds 0.32% or 54,800 shares in its portfolio.

The stock increased 2.45% or $0.74 during the last trading session, reaching $30.98. About 2,460 shares traded. Norwood Financial Corp. (NWFL) has risen 39.29% since February 18, 2017 and is uptrending. It has outperformed by 22.59% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts